Investors Homology Medicines is focused on advancing our genetic medicines platform as one-time treatments and potential cures for patients with rare diseases Overview Stock Information Stock Quote & Chart Historical Price Lookup Stock Calculator News & Events News Releases Investor Calendar Presentations Financial Information SEC Filings Annual Reports Analyst Coverage Corporate Governance Governance Highlights Management Team Board of Directors Committee Composition Investor Resources Email Alerts Contact IR Homology Medicines is focused on advancing our genetic medicines platform as one-time treatments and potential cures for patients with rare diseases News Releases Year All20232022202120202019201820172016 Date Title Nov 16, 2023 Q32 Bio and Homology Medicines Announce Merger Agreement Nov 14, 2023 Homology Medicines Reports Third Quarter 2023 Financial Results Aug 14, 2023 Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights Jul 27, 2023 Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU Jul 27, 2023 Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU May 16, 2023 Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting May 11, 2023 Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights May 03, 2023 Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting Mar 15, 2023 Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting Mar 09, 2023 Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
Year All20232022202120202019201820172016 Date Title Nov 16, 2023 Q32 Bio and Homology Medicines Announce Merger Agreement Nov 14, 2023 Homology Medicines Reports Third Quarter 2023 Financial Results Aug 14, 2023 Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights Jul 27, 2023 Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU Jul 27, 2023 Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU May 16, 2023 Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting May 11, 2023 Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights May 03, 2023 Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting Mar 15, 2023 Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting Mar 09, 2023 Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights